stockrowBioNTech SE Sponsored ADR
BNTX Healthcare Biotechnology
BioNTech SE Sponsored ADR’s revenue for fiscal 2025 (year ended December 2025) was $3.2 billion, up 9.07% from fiscal 2024.
- Revenue
- −16.4%
- EPS
- +708.4%
- Free cash flow
- −123.8%
- Total debt
- +44.4%
Quarter to September 2026, against a year earlier
Follow BNTX
Alert me
BioNTech SE Sponsored ADR (BNTX) P/S ratio
As of 5 November 2026, BioNTech SE Sponsored ADR (BNTX) trades at a P/S ratio of 7.9×. Over the past ten years it has ranged from 0.0× (September 2020) to 165× (December 2020); the current reading is higher than 69% of that period. That is below the Biotechnology industry median of 9.2× and above the Healthcare sector median of 3.5×.
P/S ratio, daily
Embed this chart
Annual newest first
| Period | P/S ratio | Change |
|---|---|---|
| FY2025 | 7.1× | (22.99%) |
| FY2024 | 9.2× | 40.70% |
| FY2023 | 6.5× | 229.80% |
| FY2022 | 2.0× | (29.22%) |
| FY2021 | 2.8× | (91.96%) |
| FY2020 | 34.8× | — |
| FY2019 | 0.0× | — |
| FY2018 | 0.0× | — |
| FY2017 | 0.0× | — |
Quarterly newest first
| Period | P/S ratio | Change |
|---|---|---|
| Sep 2026 | 9.0× | 15.09% |
| Jun 2026 | 7.8× | 10.73% |
| Mar 2026 | 7.1× | (0.51%) |
| Dec 2025 | 7.1× | 6.06% |
| 24 more quarters | Free account |
Against its own ten years
P/S ratio against peers
| Company | P/S ratio |
|---|---|
| INCY Incyte Corporation compare | 4.0× |
| ALNY Alnylam Pharmaceuticals, Inc. compare | 4.2× |
| EXEL Exelixis, Inc. compare | 6.8× |
| GMAB Genmab A/S Sponsored ADR compare | 7.9× |
| BNTX BioNTech SE Sponsored ADR | 7.9× |
| ASND Ascendis Pharma A/S compare | 13.5× |
| BBIO BridgeBio Pharma, Inc. compare | 15.5× |
| INSM Insmed, Inc. compare | 15.6× |
| ROIV Roivant Sciences Ltd. compare | 3,528× |
| Biotechnology industry median | 9.2× |
| Healthcare sector median | 3.5× |
| Market median | 1.9× |
What P/S ratio is
Price to Sales Ratio shows how much investors pay for each dollar of a company’s annual sales, whether or not it is profitable.
(Stock Price × Shares (Basic, Weighted) (latest quarter)) ÷ Revenue (TTM)
More on BNTX
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Beneish M-score
- The full statement